Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterised by extensive genomic heterogeneity and limited therapeutic options. Although recurrent coding mutations in key driver genes have been well researched, large-scale sequencing studies have identified a broad array of non-coding variants which may contribute to tumorigenesis by interfering with gene regulatory mechanisms. However, understanding the functional significance of these variants remains a major challenge due to their abundance and the complexity of non-coding regulatory structures. This review outlines current computational and experimental techniques to identify, prioritise, and functionally validate non-coding variants in PDAC. We discuss in silico methods including genome-wide association study (GWAS) fine-mapping, colocalisation, machine learning-driven functional annotation, and the use of established computational tools, in addition to epigenomic profiling technologies including, ATAC-seq, ChIP-seq, and CUT&RUN which define regulatory landscapes. We also emphasise new AI-based methods involving radiogenomics, AI imaging analysis and data integration, which provides novel potential to link genomic variation with phenotypic and imaging characteristics. Additionally, we highlight experimental validation techniques including reporter assays, electrophoretic mobility shift assays (EMSA), chromatin conformation capture methods, and CRISPR-based perturbation systems used to study variant functionality. Together, these complementary approaches establish a framework for correlating non-coding variation to regulatory mechanisms in PDAC.
No takes yet. Share an insight, caveat, or question.
Jenkac et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: